New imaging device instantly visualizes potentially harmful bacteria at POC

MolecuLight Inc. has received CE Mark approval authorizing commercial sales in the European Union of its MolecuLight i:X Imaging Device, that is revolutionizing wound care.

The MolecuLight i:X will be making its European debut at the World Union of Healing Societies (WUWHS) World Congress, September 25-29 in Florence, Italy. The company will introduce the product to wound care clinics and hospitals across Europe, demonstrating how, with the MolecuLight i:X incorporated into their clinical assessment of wound care patients, health care professionals will have access to real-time visualization of potentially harmful bacteria immediately at the bedside.

The MolecuLight i:X uses the principle of fluorescence to capture and document either still images or videos of wounds as well as their surrounding areas where potentially harmful bacteria may be present, without the need of contrast agents.

Source: MolecuLight

BD Unveils Next Generation Wireless Point-of-Care Diagnostic Device

BD announced the launch of its next generation wireless rapid diagnostic system for detection of influenza A and B, respiratory syncytial virus (RSV) and group A strep, with new traceability and secure patient health record documentation features and functionality.

The new wireless BD Veritor™ Plus System provides health care providers and laboratorians in physician offices, clinics, hospitals and integrated delivery networks (IDNs) with objective, lab-quality immunoassay test results within minutes. This rapid and accurate solution streamlines the point-of-care (POC) diagnostic workflow and enables providers to quickly review patient results to assist in determining the appropriate treatment in a single consultation. The system can help detect influenza A and B, respiratory syncytial virus (RSV) and group A strep while the patient is still on site, which enables faster decision making for an earlier intervention opportunity.

A press release can be found from BD website.

Spirometrix receives CE for its POC Breathalyzer

Spirometrix, an emerging technology healthcare company focused on research, development and commercialization of novel breath analysis devices for applications in disease diagnosis and management, announced today that its Fenom PRO™ Point-of-Care Breathalyzer has received CE marking and can now be sold in Europe.

Spirometrix Inc., founded in 2011 by Dr. Solomon Ssenyange and Ryan Leard as a personal mission to aid asthma patients in the management of their ailment, focuses on the development and commercialization of novel breath analysis devices for application in diagnosis and management of asthma. In recent years, non-invasive measurement and monitoring of the fraction of exhaled nitric oxide (FeNO) in exhaled breath has become established as the biomarker of asthma. The sensor based technology was licensed from Professor Prabir Dutta’s innovative laboratories at The Ohio State University as the company was founded.

“FeNO monitoring in the management of asthma patients at the point of care has the potential to optimize asthma therapy, improve compliance of medication use and decrease the need for emergency visits and hospitalization,” added James Wolfe, M.D., Clinical Professor of Medicine at Stanford University and a Scientific Advisor to Spirometrix. “It should be noted that both American Thoracic Society and European Respiratory Society have issued guidelines recommending FeNO testing for the assessment, management, and long-term monitoring of asthma.”

A press release can be found from Spirometrix website.